Beam Therapeutics Inc
NASDAQ:BEAM

  • LAST PRICE
    24.3600
  • TODAY'S CHANGE (%)
    1.4300 (6.2364%)
  • Bid / Lots
    24.0100/ 1
  • Ask / Lots
    24.4500/ 5
  • Open / Previous Close
    22.7500 / 22.9300
  • Day Range
    22.5200
    24.9500
  • 52 Week Range
    18.8501
    49.5000
  • Volume
    1,388,906

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
BEAM
Beam Therapeutics Inc
1.9B
-13.8x
---
GLPG
Galapagos NV
1.8B
-27.1x
---
BCRX
BioCryst Pharmaceuticals Inc
1.7B
-10.1x
---
MRVI
Maravai LifeSciences Holdings Inc
1.9B
-7.8x
---
CPRX
Catalyst Pharmaceuticals Inc
2.6B
40.8x
---
VCYT
Veracyte Inc
2.6B
-47.0x
---
As of 2024-11-04

Company Information

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.

Contact Information

Headquarters
238 Main StreetCAMBRIDGE, MA, United States 02142
Phone
857-327-8775
Fax
302-655-5049

Executives

President
Giuseppe Ciaramella
Chief Executive Officer, Principal Financial and Accounting Officer, Director
John Evans
Chief Medical Officer
Amy Simon
Chief Legal Officer and Secretary
Christine Bellon
Lead Independent Director
Mark Fishman

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.9B
Revenue (TTM)
$352.6M
Shares Outstanding
82.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.86
EPS
$-1.76
Book Value
$12.02
P/E Ratio
-13.8x
Price/Sales (TTM)
5.4
Price/Cash Flow (TTM)
---
Operating Margin
-52.31%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.